- Home
- LPCN vs WYY Comparison
LPCN vs WYY Comparison
Compare LPCN & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPCN | WYY |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 68.2M |
| IPO Year | 2011 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LPCN | WYY |
|---|---|---|
| Price | $7.34 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $15.00 | $8.67 |
| AVG Volume (30 Days) | ★ 117.3K | 38.5K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.18 | ★ 54.35 |
| EPS | N/A | ★ N/A |
| Revenue | $1,976,677.00 | ★ $142,571,749.00 |
| Revenue This Year | N/A | $5.20 |
| Revenue Next Year | $74.43 | $15.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 34.47 |
| 52 Week Low | $2.52 | $2.19 |
| 52 Week High | $12.37 | $7.55 |
Technical Indicators
Market Signals| Indicator | LPCN | WYY |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 42.61 |
| Support Level | $2.87 | $3.96 |
| Resistance Level | $8.35 | $4.99 |
| Average True Range (ATR) | 0.79 | 0.29 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 8.57 | 63.11 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.